Moderna, Inc.
As of Oct 22, 2026, Moderna is in Stage 2, the uptrend phase, now in week 17 (since Jun 25, 2026). It closed at $202.63, 17.6% below its 52-week high and above its 200-day average, which is rising.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is MRNA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MRNA among Biotechnology4th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
Moderna: quick answers
What stage is Moderna in?
As of Oct 22, 2026, Moderna (MRNA) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 25, 2026 and is in week 17. What the four stages mean
Is Moderna in an uptrend?
Yes. Moderna is in a Stage 2 uptrend. It trades 149.1% above its 200-day average, which is rising.
How far is Moderna from its 52-week high?
Moderna closed at $202.63 on Oct 22, 2026, 17.6% below its 52-week high of $245.81. Its 52-week low is $22.36.
How has Moderna performed over the past year?
As of Oct 22, 2026, Moderna is up 637.1% over the past year and up 556.6% so far in 2026.
Which sector and industry is Moderna in?
Moderna is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.